Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has given written informed consent~2. Patient is 18 years or older~3. Patient has histologically confirmed prostate cancer~4. Patient has a serum prostate-specific antigen (PSA) level at screening \>2 ng/mL~5. The prostate size is \>30 cubic centimetres (cc), measured by TRUS~6. Patient has had a bone-scan within 12 weeks before inclusion~7. Patient must be able to undergo transrectal examinations~8. Patient has an estimated life expectancy of at least 12 months~Exclusion Criteria:~1. Any previous treatments for prostate cancer~2. Previous trans-urethral resection of the prostate (TURP)~3. Is not considered a candidate for medical castration~4. Use of urethral catheter~5. Is currently treated with a 5-alpha reductase inhibitor~6. Is currently treated with an alpha-adrenoceptor antagonist~7. Treatment with botulinum toxin A (Botox)~8. Require radiotherapy during the trial~9. History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema~10. Hypersensitivity towards any component of the investigational products or excipients~11. Previous history or presence of another malignancy~12. A clinically significant disorder~13. A corrected QT interval over 450 msec~14. Mental incapacity or language barrier precluding adequate understanding or co-operation~15. Receipt of an investigational drug within the last 28 days proceeding screening~16. Previous participation in any degarelix trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/80 mg (Type: EXPERIMENTAL): The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
- Goserelin (3.6 mg) + bicalutamide (50 mg) (Type: ACTIVE_COMPARATOR): Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.

Based on this trial design, predict the completion outcome and termination type (if applicable).